Carregant...
晚期非小细胞肺癌三线治疗疗效及生存分析
BACKGROUND AND OBJECTIVE: The appearance of highly effective and low toxic drugs enables an increasing number of advanced non-small cell lung cancer (NSCLC) patients to receive third-line therapy. No other standard choice for third-line therapy aside from erlotinib is possible. This study respective...
Guardat en:
| Publicat a: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
中国肺癌杂志编辑部
2012
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6000300/ https://ncbi.nlm.nih.gov/pubmed/22681924 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2012.06.08 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|